UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 


FORM 6-K



REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of May, 2021
 
Commission File Number: 001-38283
 

 
InflaRx N.V.
(Translation of registrant's name into English)



Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)


 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F ☒         Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
 


INFLARX N.V.
 
On May 11, 2021, InflaRx N.V. issued a press release titled “InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
INFLARX N.V.
   
Date: May 11, 2021
By:
/s/ Niels Riedemann
 
Name:
Niels Riedemann
 
Title:
Chief Executive Officer

3

EXHIBIT INDEX
 
Exhibit No.
 
Description
 
Press Release, dated May 11, 2021


 4

InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more InflaRx NV Charts.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more InflaRx NV Charts.